Prostate Cancer Trial, Recruiting NCT05762198 Sponsor: Chinese University of Hong Kong Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT05762198
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between 50 and 80 years of age
  • People whose urinary retention (inability to pass urine) has not improved with standard treatments and is caused by a condition called benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland
  • People who currently have a urinary catheter (a thin tube inserted to drain the bladder) in place before treatment begins
  • People whose prostate size measures between 30 and 80 millilitres on an ultrasound scan

Who may not be able to join:

  • People who have previously had surgery on the prostate
  • People with a past or current diagnosis of prostate cancer
  • People where there is a strong suspicion of prostate cancer — for example, those with a raised PSA level before urinary retention occurred, or an abnormal prostate finding on a physical examination that has not yet been fully investigated
  • People known to have a narrowing of the urethra (the tube that carries urine out of the body), bladder stones, or a bladder that does not contract properly
  • People with a known neurological condition that may affect how the bladder works, such as Parkinson's disease or a history of stroke
  • People for whom the standard surgical procedures used in this trial would not be considered safe — for example, those who are not medically fit for anaesthesia, have an active urinary tract infection, cannot be positioned appropriately for the procedure, have an uncorrectable bleeding disorder, or are taking blood-thinning medications that cannot be safely stopped (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Ka-Fung CHIU, FRCS, PhD, Chinese University of Hong Kong

Phone: 35051663

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2023
Est. completion
30 April 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Changes in International Prostate Symptom Score (IPSS) at 12 months after treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov